Pliant Therapeutics Inc (PLRX) Stock Price, Quote & News

Company Profile

Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonal...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 481 6770

Website: pliantrx.com

Address:

331 Oyster Point Boulevard, South San Francisco, United States

NolAsrtormZ Sep. 7 at 6:37 PM

$GRI 200million Market cap is aprx $85 a share. Note* $PLRX traded and carried a 900 MILLION $ Market cap while they in their iPf trial. Once they discontinued iPF trial their Market cap went to Aprx 100 million market cap. How much is ipf trial market cap worth?

0 · Reply

PhantomDivine Sep. 7 at 7:47 AM

$PLRX Looks good. But everyone also should have SKYQ on their watch list, the potential here is immense.

0 · Reply

NolAsrtormZ Sep. 5 at 10:30 PM

$GRI another example of big Market Cap with companies doing iPf trials $PLRX was trading at 900 Million market cap during their iPf trial. Once they discontinued iPf trial they trade at aprx 114 million market cap

0 · Reply

MadHatterTrades74 Sep. 5 at 7:54 PM

$PLRX Great day!

0 · Reply

stoneblood Sep. 5 at 6:34 PM

$PLRX flying under the radar catching some nice bids on volume

0 · Reply

kshonstocks Sep. 5 at 4:26 PM

stevie cohen $PLRX https://www.sec.gov/Archives/edgar/data/1746473/000090266425003977/xslSCHEDULE_13G_X01/primary_doc.xml

0 · Reply

NolAsrtormZ Sep. 5 at 2:56 PM

$GRI ...$PLRX traded about 900 million market cap when they were in mid iPf trial....so, just an example of what iPf is worth. Now look at plrx... take away iPf study worth...103million market cap. Gri is at 3.8million market cap

0 · Reply

NolAsrtormZ Sep. 5 at 1:19 PM

$PLRX whos got the iPf data now? $GRI 🤑

0 · Reply

BearishAlgo Sep. 4 at 11:21 PM

$PLRX

0 · Reply

MrPheonix Sep. 4 at 10:29 PM

$PLRX news?

0 · Reply

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Jun 27, 2025, 4:05 PM EDT - 2 months ago

Pliant Therapeutics Provides Update on BEACON-IPF

May 21, 2025, 4:03 PM EDT - 3 months ago

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

May 8, 2025, 4:05 PM EDT - 4 months ago

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 1, 2025, 4:05 PM EDT - 4 months ago

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

Apr 7, 2025, 4:05 PM EDT - 5 months ago

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

Apr 3, 2025, 12:22 PM EDT - 5 months ago

Pliant Therapeutics: An Activist On Deck

$Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors$

Mar 17, 2025, 8:00 AM EDT - 6 months ago

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Mar 13, 2025, 11:04 AM EDT - 6 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

Mar 13, 2025, 7:20 AM EDT - 6 months ago

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

Mar 3, 2025, 4:05 PM EST - 6 months ago

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Mar 3, 2025, 1:32 PM EST - 6 months ago

Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder

Mar 3, 2025, 9:27 AM EST - 6 months ago

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Mar 2, 2025, 11:00 AM EST - 6 months ago

The Schall Law Firm Invites Shareholders With Losses In Pliant Therapeutics, Inc. To Join A Securities Fraud Investigation

Feb 27, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Shareholders to Inquire about Securities Investigation

Feb 26, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Connect

Feb 25, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Reach Out

Feb 24, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Shareholders to Learn More About the Investigation

Feb 23, 2025, 10:00 AM EST - 7 months ago

Pliant Therapeutics, Inc. (PLRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 21, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Connect

Feb 20, 2025, 3:39 PM EST - 7 months ago

PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Feb 20, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Stockholders to Inquire about Securities Investigation

Feb 19, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Investors to Learn More About the Investigation

Feb 18, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Stockholders to Learn More About the Investigation

Feb 17, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Investors to Inquire about Securities Investigation

Feb 16, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Reach Out

NolAsrtormZ Sep. 7 at 6:37 PM

0 · Reply

PhantomDivine Sep. 7 at 7:47 AM

$PLRX Looks good. But everyone also should have SKYQ on their watch list, the potential here is immense.

0 · Reply

NolAsrtormZ Sep. 5 at 10:30 PM

0 · Reply

MadHatterTrades74 Sep. 5 at 7:54 PM

$PLRX Great day!

0 · Reply

stoneblood Sep. 5 at 6:34 PM

$PLRX flying under the radar catching some nice bids on volume

0 · Reply

kshonstocks Sep. 5 at 4:26 PM

stevie cohen $PLRX https://www.sec.gov/Archives/edgar/data/1746473/000090266425003977/xslSCHEDULE_13G_X01/primary_doc.xml

0 · Reply

NolAsrtormZ Sep. 5 at 2:56 PM

0 · Reply

NolAsrtormZ Sep. 5 at 1:19 PM

$PLRX whos got the iPf data now? $GRI 🤑

0 · Reply

BearishAlgo Sep. 4 at 11:21 PM

$PLRX

0 · Reply

MrPheonix Sep. 4 at 10:29 PM

$PLRX news?

0 · Reply

premarketmaker Sep. 4 at 10:07 PM

this is me if anyone wants to sell $PLRX

0 · Reply

MadHatterTrades74 Sep. 4 at 9:36 PM

$PLRX Massive buy today by point72 asset management. 🙌

0 · Reply

BearishAlgo Sep. 4 at 9:14 PM

$PLRX approaching a key resistance area around $1.80 - $1.95. Watching for a reaction here. If it breaks, I'd use this zone as support for a long position

0 · Reply

NolAsrtormZ Sep. 4 at 4:42 PM

$GRI ....$PLRX traded at 900 million market cap with their on going iPf trial. Whats 900 million market cap with a 2.5million share float???? $XBI

0 · Reply

NolAsrtormZ Sep. 4 at 2:55 PM

$PLRX iPf data seems to be super lucrative. Uthr stock gained like 5 billion in market cap. Wonder if gri bio will pump🤑

0 · Reply

NVDAMillionaire Sep. 4 at 9:25 AM

$PLRX Really good write-up that perfectly summarizes PLRX's present situation. So if you want to bring your PLRX knowledge up to date or just discover PLRX, this is required reading. https://beyondspx.com/quote/PLRX/pliant-therapeutics-a-strategic-pivot-after-setback-unlocks-platform-potential-nasdaq-plrx#analysis

0 · Reply

wavw Aug. 27 at 5:02 PM

$PLRX have they resumed their trial…looking this after a long time

0 · Reply

nUme22 Aug. 20 at 11:59 PM

$PLRX gimme 5....common now

0 · Reply

DARKP00L Aug. 13 at 3:19 PM

$PLRX this stock is attracting a lot of interest. Be prepared for possible changes!

0 · Reply

JarvisFlow Aug. 8 at 11:31 AM

Piper Sandler has adjusted their stance on Pliant Therapeutics ( $PLRX ), setting the rating to Overweight with a target price of 17 → 4.

0 · Reply

Sholtzc Aug. 6 at 7:48 PM

$PLRX What a twisted pos

0 · Reply

Bellbent Aug. 5 at 1:59 PM

$PLRX sold, bringing my money over to $SSKN, been a sweet ride from 1.11 Pliant. Thank you!

0 · Reply

Market Cap	106.20M
Revenue (ttm)	0.00
Net Income (ttm)	-210.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.14

Volume	496,500
Avg Vol	1,128,792
Day's Range	N/A - N/A
Shares Out	61.39M
Stochastic %K	60%
Beta	1.43
Analysts	Sell
Price Target	$2.96